Gocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease. While amantadine has been available as an anti-Parkinson drug since 1968, the specific formulation in Gocovri was approved in August 2017 following investigations into the effect of N-methyl-D-aspartate receptor antagonists on dyskinesia. Gocovri is administered once daily at bedtime, allowing for amantadine levels to slowly increase during the night and peak in the early morning, when dyskinesia episodes are most frequent.
LIST OF FIGURES
9 Figure 1: Gocovri for Parkinson’s disease – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Gocovri for Parkinson’s disease
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Gocovri for Parkinson’s disease
13 Figure 4: Gocovri sales for Parkinson’s disease in the US, 2016–25
LIST OF TABLES
5 Table 1: Gocovri drug profile
7 Table 2: Gocovri pivotal trial data in Parkinson’s disease
13 Table 3: Gocovri sales for Parkinson’s disease in the US ($m), 2016–25
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726